GSK FINANCE (NO 2) LIMITED
Get an alert when GSK FINANCE (NO 2) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
—
Latest balance sheet
Net assets
£20bn
USD 26,893,992,000
0% vs 2024
Employees
—
Average over period
Profit before tax
£11m
USD 15,199,000
+156% highest in 3 filed years
Net assets
3-year trend · vs Consumer Discretionary median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | — | — | — | — | |
| Operating profit | -£83,243,404 | -£20,170,940 | £11,296,172 | +156% | |
| Profit before tax | -£83,243,404 | -£20,170,940 | £11,296,172 | +156% | |
| Net profit | -£87,330,360 | -£13,797,845 | £8,523,226 | +161.8% | |
| Cash | — | — | — | — | |
| Total assets less current liabilities | £18,633,813,452 | £20,715,217,391 | £20,717,597,919 | 0% | |
| Net assets | £17,905,938,313 | £19,979,579,339 | £19,988,102,564 | 0% | |
| Equity | £17,905,938,313 | £19,979,579,339 | £19,988,102,564 | 0% | |
| Average employees | 0 | 0 | — | — | |
| Wages | — | — | — | — | |
| Directors' remuneration | £0 | £0 | £0 | — |
Figures converted to GBP from USD at 0.743 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Return on capital employed | -0.4% | -0.1% | 0.1% | |
| Gearing (liabilities / total assets) | 13.4% | 3.7% | 3.7% | |
| Current ratio | 0.01x | 0.71x | 31.85x | |
| Interest cover | -0.93x | -0.19x | 0.40x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors have taken into account that as part of the Group, the Company has the support from the Group through the access to the Group cash pooling mechanism and can take actions to ensure business continuity through operational channels, as well as the ability to manage variable costs. On the basis of those considerations, the Directors believe that it remains appropriate to adopt the going concern basis of accounting in preparing the financial statements.”
Group structure
- GSK FINANCE (NO 2) LIMITED · parent
- Affinivax, Inc. 100%
- Aiolos Bio Limited 100%
- Aiolos Bio, Inc. 100%
- BP Asset IX, Inc. 100%
- Cellzome GmbH 100%
- Colleen Corporation 100%
- Corixa Corporation 100%
- Elsie Biotechnologies, Inc. 100%
- Glaxochem (UK) Unlimited 43.14%
- GlaxoSmithKline Biologicals S.A.S. 20.4%
- GlaxoSmithKline Biologicals SA 20.4%
- GlaxoSmithKline Brasil Limitada 39.57%
- GlaxoSmithKline Capital Inc. 100%
- GlaxoSmithKline Chile Farmaceutica Limitada 100%
- GlaxoSmithKline Holdings (Americas) Inc. 100%
- GlaxoSmithKline International Limited 20.4%
- GlaxoSmithKline LLC 100%
- GlaxoSmithKline SL LLC 100%
- GlaxoSmithKline SL LP 100%
- GSK Equity Investments, Limited 100%
- Human Genome Sciences, Inc. 100%
- IDRX, INC. 100%
- J&J Technologies, LC 100%
- Laboratorios Stiefel Ltda. 4.76%
- SmithKline Beecham (Investments) Limited 44.96%
- Stiefel Laboratories (U.K.) Ltd 37.18%
- Stiefel Laboratories, Inc. 100%
- Stiefel Research (Australia) Holdings Pty Ltd 100%
- Stiefel Research Australia Pty Ltd 100%
- Stiefel West Coast LLC 100%
- Strebor Inc. 100%
- Tesaro Development, Ltd. 100%
- Tesaro Bio GmbH (in liquidation) 100%
- Tesaro Bio Netherlands B.V 100%
- Tesaro UK Limited 100%
- Tesaro, Inc. 100%
Significant events
- “On 14 April 2026, the Company received a capital injection of $989m from GSK Finance plc and made a capital injection into Ontario Inc of $989m to facilitate an acquisition. On the same day the Company received a return of capital from Triton AmalCo (formerly Ontario Inc) for $810m, representing the proceeds of the internal sale of intellectual property from the acquisition, and paid a dividend to GSK Finance plc for the same amount.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| WHYTE, Victoria Anne | Secretary | 2018-12-12 | — | — |
| BROWN, Julie Belita | Director | 2023-05-01 | Mar 1962 | British |
| WALKER, Adam | Director | 2018-12-12 | Nov 1967 | British |
| WOODTHORPE, Timothy John | Director | 2026-03-02 | Jan 1979 | British |
| EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Director | 2018-12-12 | — | — |
| THE WELLCOME FOUNDATION LIMITED | Corporate Director | 2018-12-12 | — | — |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DINGEMANS, Simon Paul | Director | 2018-12-12 | 2019-05-01 |
| MACKAY, Iain James | Director | 2019-05-01 | 2023-05-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Glaxosmithkline Finance Plc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-12-12 | Active |
Filing timeline
Last 20 of 47 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-14 | AA | accounts | Accounts with accounts type full | |
| 2026-05-08 | SH01 | capital | Capital allotment shares | |
| 2026-03-03 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-07-10 | AA | accounts | Accounts with accounts type full | |
| 2024-10-11 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-09-27 | SH01 | capital | Capital allotment shares | |
| 2024-09-23 | CH01 | officers | Change person director company with change date | |
| 2024-09-23 | CH03 | officers | Change person secretary company with change date | |
| 2024-09-17 | CH01 | officers | Change person director company with change date | |
| 2024-09-11 | CH02 | officers | Change corporate director company with change date | |
| 2024-09-11 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2024-09-11 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-07-18 | AD02 | address | Change sail address company with new address | |
| 2024-07-16 | AA | accounts | Accounts with accounts type full | |
| 2023-10-11 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-07-24 | AA | accounts | Accounts with accounts type full | |
| 2023-06-27 | SH01 | capital | Capital allotment shares | |
| 2023-05-11 | AP01 | officers | Appoint person director company with name date | |
| 2023-05-11 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 2
- Officers appointed
- 1
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.